ITM Isotope Technologies Munich SE acquired by Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited agreed to acquire ITM Isotope Technologies Munich SE, a German radiopharmaceuticals brand.
Transaction summary
- Target
- ITM Isotope Technologies Munich SE
- Acquirer
- Telix Pharmaceuticals Limited
- Seller
- ITM shareholders
- Announced
- -
- Geography
- Germany
- Tags
- BiotechDrug DevelopmentRadioisotope ManufacturingRadiopharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-09-24
- Latest update
- 2026-09-25
Value and multiples
Price / value
USD 1.6B
Consideration | USD
Basis: Public source
Price / revenue
6.04x
Period: FY
Basis: Derived from source data
Price / EBITDA
-
EBITDA basis not stated
Basis: Derived from source data
Basis
- USD 1.6bn consideration is treated as publicly disclosed or derived directly from public source data.
- Implied Price / revenue is 6.04x, calculated from USD 1.6bn value and USD 273m revenue.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- Metric period: FY.
Source summary
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
ConfirmedTelix announced on 2026-09-20 that it would acquire 100% of ITM for US$1.65bn upfront, plus up to US$700m contingent consideration. BioSpace reported ITM revenue of $273m for 2025; the upfront consideration divided by that reported revenue implies a derived 6.04x price/revenue multiple. The deal was announced, not reported closed, in the supplied evidence.
Open sourceTelix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
ConfirmedTelix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’ | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search People also ask Loading questions... Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’ Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote. Published Sept. 21, 2026 Ben Fidler Lead Editor Share Copy link Email LinkedIn X/Twitter Facebo
Open source